Atea Pharmaceuticals, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual Form 10-K, not a standalone fourth-quarter filing. Atea is a clinical-stage biopharmaceutical company with no approved products or commercial product revenue.
Business context and development programs
- Lead candidate bemnifosbuvir is being developed as an oral treatment for high-risk, non-hospitalized COVID-19 patients and potentially in combination with another antiviral.
- In November 2022, Atea initiated SUNRISE-3, a global Phase 3 trial targeting at least 1,500 high-risk patients. The primary endpoint is all-cause hospitalization or death through Day 29 in the supportive-care population.
- Atea plans to initiate a Phase 2 trial of bemnifosbuvir plus ruzasvir for treatment-naive HCV patients in the second quarter of 2023. The planned regimen is eight weeks, with approximately 280 patients.
- In February 2023, Atea discontinued further clinical development of AT-752 for dengue and ended discovery efforts for an RSV candidate to concentrate resources on COVID-19 and HCV programs.
- The Roche license agreement terminated effective February 10, 2022. Atea regained worldwide rights to bemnifosbuvir and became responsible for related development costs.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Collaboration revenue | $0 | $351.4 million | Down $351.4 million |
| Research and development expense | $81.9 million | $167.2 million | Down $85.3 million |
| General and administrative expense | $48.7 million | $45.8 million | Up $2.9 million |
| Total operating expenses | $130.7 million | $213.0 million | Down $82.3 million |
| Operating income (loss) | $(130.7) million | $138.4 million | Down $269.0 million |
| Interest income and other, net | $11.2 million | $0.2 million | Up $10.9 million |
| Net income (loss) | $(115.9) million | $121.2 million | Down $237.1 million |
| Basic loss per share | $(1.39) | $1.46 | Unfavorable change |
- Cash and liquidity: Cash, cash equivalents and marketable securities totaled $646.7 million at December 31, 2022, including $188.5 million of cash and cash equivalents and $458.2 million of marketable securities.
- Cash flow: Net cash used in operating activities was $121.0 million, compared with $87.0 million in 2021. Net cash used in investing activities was $455.4 million, primarily reflecting purchases of marketable securities. Net cash provided by financing activities was $0.4 million.
- Runway: Management expects available financial resources to fund currently planned activities into 2026, although this estimate depends on assumptions regarding clinical costs, timing and capital requirements.
- Debt and obligations: The filing does not report conventional debt financing. Total liabilities were $26.1 million, including $3.1 million of operating lease liabilities and $5.3 million of income taxes payable. The Boston office lease requires total remaining payments of $3.3 million through 2026.
- Other financial items: Stock-based compensation expense was $46.7 million in 2022. Marketable securities had $0.7 million of unrealized losses, recorded in other comprehensive loss.
- Margins: Operating and net margins are not meaningful because the company had no 2022 revenue and remains dependent on research and development financing.
Material changes versus the prior comparable period
- Revenue fell to zero in 2022 after Atea recognized $351.4 million of remaining Roche-related deferred revenue in 2021 following Roche’s termination notice.
- Research and development expense declined primarily because Roche cost-sharing obligations ended; Atea recorded a $6.9 million net credit related to Roche closeout adjustments in 2022.
- Despite lower total operating expenses, Atea returned to a substantial operating and net loss because the 2021 Roche accounting revenue did not recur.
- Interest income increased substantially because of higher interest rates and investment of cash in higher-yielding marketable securities.
- Atea’s cash and investment portfolio declined from $764.7 million of cash, cash equivalents and restricted cash at year-end 2021 to $188.7 million at year-end 2022, partly reflecting operating cash use and purchases of marketable securities. Total cash, cash equivalents and marketable securities were $646.7 million at year-end 2022.
- The company expanded its equity-based compensation structure, ending 2022 with 13.6 million outstanding stock options, 161,750 restricted stock units and 724,970 performance-based restricted stock units.
Guidance, outlook, risks and unusual items
- Management expects substantially higher spending as SUNRISE-3 advances, the HCV Phase 2 program begins, manufacturing capacity expands and the company conducts discovery and potential IND-enabling work for a protease inhibitor.
- Atea expects no product revenue for the foreseeable future and may require additional capital. It has an equity sales agreement permitting issuance of up to $200.0 million of common stock; no shares had been issued under that agreement as of December 31, 2022.
- Key clinical uncertainty remains: prior studies did not meet all primary endpoints. MORNINGSKY did not achieve its primary symptom-alleviation endpoint and was discontinued early, although an exploratory secondary analysis showed a 71% reduction in hospitalization.
- SUNRISE-3 is sensitive to background hospitalization rates. Management states that the trial design assumes a placebo hospitalization rate of at least 4%; lower rates could require more patients, higher costs or a longer study.
- Bemnifosbuvir faces competition from Paxlovid, Lagevrio, remdesivir and multiple investigational antivirals. The COVID-19 market may shrink as vaccination, existing treatments or changing disease severity affect demand.
- The company relies on third-party CROs and CMOs. Ruzasvir’s active pharmaceutical ingredient suppliers are located in China, and regulatory starting-material suppliers for all product candidates are located in China, creating supply-chain and geopolitical exposure.
- Under the Merck license for ruzasvir, Atea may owe up to $135 million in development and regulatory milestones, up to $300 million in sales milestones and tiered royalties ranging from high single digits to mid-teens percentages on net sales.
- Atea reported no material legal proceedings. Management and KPMG concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2022; KPMG issued unqualified audit opinions.
Most important facts for investors to verify
- Enrollment progress, interim review and eventual efficacy and safety results from the SUNRISE-3 Phase 3 trial.
- Whether COVID-19 hospitalization rates remain high enough for the SUNRISE-3 design to produce a meaningful and interpretable result.
- Timing and execution of the planned Phase 2 HCV trial of bemnifosbuvir plus ruzasvir, including sustained virologic response and resistance outcomes.
- Actual cash burn, investment maturities and whether the stated runway to 2026 remains valid as clinical and manufacturing spending increases.
- Potential dilution or financing needs under the $200 million equity sales agreement and from additional capital raises.
- Ruzasvir milestone, royalty and supply obligations, including dependence on Chinese suppliers.
- Regulatory developments affecting COVID-19 emergency authorizations, commercial reimbursement and the transition from government procurement to commercial payer channels.
- Patent prosecution and opposition risks, particularly for bemnifosbuvir and ruzasvir, and the scope and enforceability of related intellectual-property protection.